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Background: Elevated cardiac troponin levels are consistent with the diagnosis of an acute coronary syndrome, but
may also represent adverse drug reactions. Psychostimulating drugs raise both blood pressure and heart rate, and
case reports of sudden death, stroke, and myocardial infarction have led to regulatory and public concern about
the cardiovascular safety of these drugs.
Case presentation: We present a case where a 41-year-old Norwegian male with radiating chest pain, elevated
troponins, and supraventricular tachycardia was hospitalized. Tentative diagnosis was acute coronary syndrome.
Percutaneous coronary angiography, but not cardiac magnetic resonance imaging, was performed and medical
antiplatelet treatment started. Because of an attention deficit/hyperactivity disorder the patient had recently
increased his dose of methylphenidate, but still within the therapeutic dose range. Apart from venlafaxine, also
in a therapeutic dose, the patient took no other drugs. An acute coronary syndrome was excluded during
hospitalization, and a drug effect was suspected.
Conclusions: When interpreting troponin results it is important to take into account the context of the patient’s
clinical presentation, including the possibility of adverse drug reactions. The adverse drug reaction could include a
combination of vasospasm and/or increased oxygen demand due to tachycardia. This case should be borne in
mind before a diagnosis of myocardial infarction is given, or a decision to perform invasive coronary angiography is
made in patients that use methylphenidate or related substances. Cardiac magnetic resonance imaging could be of
diagnostic value in such cases.
Keywords: Supraventricular tachycardia, Troponin, Methylphenidate, Venlafaxine, Acute coronary syndrome,
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Elevated cardiac troponin levels are consistent with the
diagnosis of an acute coronary syndrome, but may also
represent adverse drug reactions. Psychostimulating drugs
raise both blood pressure and heart rate, and case reports
of sudden death, stroke, and myocardial infarction (MI)
have led to regulatory and public concern about the car-
diovascular safety of these drugs [1]. Methylphenidate
(Ritalin®) is used for the treatment of attention-deficit
hyperactivity disorder (ADHD) and misused recreationally
and as a cognitive enhancer. Methylphenidate inhibits the* Correspondence: lisa.drange.hole@helse-bergen.no
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article, unless otherwise stated.dopamine and norepinephrine transporters thereby ele-
vating dopamine and norepinephrine levels in the brain
[2]. In the Summary of Product Characteristics (SPC) for
Ritalin®, tachycardia is reported as a common adverse re-
action (≥1/100 to < 1/10), chest pain is reported as less
common (≥1/1000 to < 1/100), angina pectoris is reported
as a rare adverse reaction (≥1/10 000 to < 1/1000), and
supraventricular tachycardia (SVT) and MI are reported
as < 1/10 000 or unknown. Venlafaxine (Efexor Depot®) is
a selective monoamine reuptake inhibitor. In the SPC for
Efexor Depot®, tachycardia is reported as a less common
adverse reaction (≥1/1000 to < 1/100), ventricular tachycar-
dia and torsades de pointes are reported as rare (≥1/10 000
to < 1/1000) [3]. The Regional Medicines Information and
Pharmacovigilance Centre (RELIS) in Norway have the
responsibility for regional pharmacovigilance based on atral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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present report was submitted to RELIS in September 2013.
The report represented a suspected, but not con-
firmed, acute coronary syndrome in a 41-year-old male
treated with methylphenidate. The presentation of the
case follows the guidelines for submitting adverse drug
reaction for publication [4].
Case presentation
Case report: A 41-year-old Norwegian male with ADHD
was admitted to hospital because of tachycardia, chest
pain and radiation of pain to his right arm and neck. A
week prior to hospitalization his general practitioner in-
creased the patient’s Ritalin® dose from 60 to 80 mg daily
plus three 10 mg tablets, if needed, per day. The patient
also used 75 mg of Efexor Depot® × 1 daily because of
anxiety. Previous drug abuse was reported, but the pa-
tient was now only taking prescribed medication. The
patient had previously experienced heart palpitations,
but never persistent tachycardia. He had never been hos-
pitalized before. The tachycardia and chest pain com-
menced while the patient was seated, not in relation to
increased physical activity, and lasted approximately two
hours, with concomitant nausea. At admission, blood
pressure was 113/79 mmHg and heart rate was 200 bpm.
Electrocardiogram (ECG) showed an SVT with a fre-
quency of 200 beats per minute (bpm). There was no
ST-segment elevation. Cardiac troponin I (cTnI) was
82 (<30 ng/L), 6 hours later 616 and 12 hours later 529.
Creatine kinase (CK) was 10 (<5 ug/L). Carotic massage
had no effect on his tachycardia. However, the patient
converted to sinus rhythm spontaneously 15 minutes after
arriving at the hospital. At conversion to sinus rhythm, his
ECG was still without ST-segment elevation. In accor-
dance with the European Society of Cardiology guidelines
for the management of acute coronary syndromes in pa-
tients presenting without persistent ST-segment elevation
[5], the patient was given 300 mg acetylsalicylic acid
(Acetylsalisylsyre®) and 180 mg ticagrelor (Brilique®) orally
as a starting dose, and the following two days before
dismissal from the hospital 75 mg acetylsalicylic acid
and 90 mg ticagrelor x 2 per day and 10 mg atorvastatin
(Lipitor®). The patient was observed, and reported no
further pain or distress. Because of elevated cTnI and CK
levels and because of his cardiovascular risk factors of
heritage, smoking, gender and clinical presentation, fur-
ther examinations were carried out: Cardiac ultrasound
showed minimal hypokinesia in the proximal lower wall of
the left ventricle, but adequate systolic function with an
ejection fraction (EF) > 60% (normal). Percutaneous cor-
onary angiography was performed showing no pathology.
Acetylcholine provocation test was not performed during
the angiography. No further cardiac investigations, inclu-
ding cardiac magnetic resonance imaging (CMR), wereperformed. SVT and elevated troponin levels were inter-
preted as related to ingestion of methylphenidate and ven-
lafaxine. His methylphenidate dose was reduced to 30 mg
times 2 daily, with no additional 10 mg tablets. The pa-
tient was dismissed from hospital.
Discussion
Methylphenidate is used in treatment of ADHD from
the age of six. In Norway, methylphenidate is not ap-
proved as treatment for adults, because safety and effect
of the drug is not documented according to the SPC.
However, most guidelines recommend methylphenidate
as first-line medication for ADHD in adults [6]. When
consulting Embase and PubMed, no interactions are re-
ported between venlafaxine and methylphenidate. In the
present case an acute coronary syndrome was excluded,
and we believe his troponin rise and symptoms could be
an adverse drug reaction. Maximum dose methylphenid-
ate is 60 mg/day in children and 80–100 mg/day in
adults. However, an exact maximum dose has not been
determined. Recommended starting dose of venlafaxine
depot capsules is 75 mg as a single dose daily. Patients
that do not respond to the starting dose might benefit
from an increased dose, up to a maximum dose of
225 mg/day. Our patient states retrospectively that he
took 40 mg methylphenidate in the morning and 40 mg
at night. He did not take any 10 mg tablets of methyl-
phenidate the week prior to hospitalization. Both me-
thylphenidate and venlafaxine have been associated with
cardiovascular effects, including tachycardia. Further-
more, one cannot rule out a pharmacodynamic inter-
action between the two drugs for the SVT and troponin
elevation. One study investigated whether use of methyl-
phenidate in adults is associated with elevated rates of
serious cardiovascular events compared with rates in
nonusers. Although initiation of methylphenidate was
associated with a 1.8-fold increase in risk of sudden
death or ventricular arrhythmia, the lack of a dose–
response relationship suggests that this association may
not be a causal one [1].
One case report describes a man, aged 27, whom
suffered an acute anterolateral MI related to use of pre-
scribed methylphenidate (5 mg twice daily for adult
attention deficit disorder) [7]. During the night pre-
ceding his hospitalization, the patient had taken three
extra 5 mg doses (totaling 25 mg over a 24 hour period)
of methylphenidate. Blood pressure, pulse, respiratory
frequency and temperature were normal, however ECG
showed > 1 mm ST-elevation in leads I, AVL, V5 and V6.
cTnI was 9.32 ng/mL. Cardiac catheterization was nor-
mal, but there was severe inferolateral hypokinesia,
consistent with MI. The cardiology service believed that
the acute MI was due to vasospasm caused by methyl-
phenidate. The authors of this case report suggest that
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from the usual treatment given to patients with coronary
artery disease, because these events are more likely to
occur in a younger population without significant co-
ronary artery disease, and the mechanism is likely to be
due to coronary artery vasospasm [7]. Based on this ob-
servation and on our case report, one might argue that
sympathomimetic-induced MI should be treated with
aspirin, nitrates and benzodiazepines initially, until the
underlying cause of myocardial ischemia has been re-
solved [8].
Coronary artery spasm is an important cause of myo-
cardial ischemia, and can lead to acute MI, ventricular
arrhythmias and sudden death [9]. The pathological me-
chanisms leading to coronary artery spasm are not fully
understood. The degree of vasoconstriction can vary from
complete occlusion to minimal contraction of an artery
segment. Ischemia occurs when the oxygen demand in the
myocardium becomes larger than the oxygen supply.
Coronary artery spasm is known to be caused by hy-
perventilation, cocain, tobacco, histamin, serotonin and
acetylcholine [10].
Regarding methylphenidate, it seems plausible that the
combination of adrenergic and cholinergic actions of
this drug may disrupt the coronary autonomic balance
in favor of coronary vasoconstriction [11]. A dynamic
stenosis associated with such a coronary vasospasm can
limit the supply of oxygen and nutrients and, in the
worst case, precipitate MI.
The diagnosis of coronary vasospasm is based upon the
angiographic finding of epicardial coronary narrowing that
is promptly reversed by vasodilators. If normal coronaries
are found at angiography, the diagnosis usually becomes
one of exclusion based on clinical and electrocardio-
graphic criteria [11]. A coronary spasm provocation test
can be performed. The test involves intracoronary injec-
tion of acetylcholine in patients who show no culprit le-
sion on coronary angiography and are suspected to have
coronary spasm as the cause of chest pain [12]. In our case
the coronary angiography was negative. An acetyl choline
provocation test was not performed, which is a limitation
to our case report. Acetyl choline provocation tests are
not routinely performed in Norwegian hospitals. Cardiac
ultrasound showed minimal hypokinesia in the proximal
lower wall of the left ventricle, but adequate systolic func-
tion with a normal EF. His ECG showed no signs of on-
going ischemia, but an SVT with a frequency of 200 bpm.
cTnI elevation might be caused by the SVT or an episode
of coronary artery spasm that occurred, and remitted
spontaneously, before angiography was performed. This
might explain the minimal hypokinesia caught on the car-
diac ultrasound, however, not depicted on the ECG.
A consensus statement published to give a universal def-
inition of the term MI, classifies MI into various subtypes[13]: Type 1 is a spontaneous MI related to ischemia from
a primary coronary event (e.g., plaque rupture, thrombotic
occlusion). Type 2 is secondary to ischemia from a
supply-and-demand mismatch. Type 3 is an MI resulting
in sudden cardiac death. Type 4a is an MI associated with
percutaneous coronary intervention, and 4b is associated
with in-stent thrombosis. Type 5 is an MI associated with
coronary artery bypass surgery. According to this consen-
sus, our patient experienced a type 2 MI, where SVT and/
or a dynamic stenosis associated with a coronary vaso-
spasm limited the supply of oxygen and nutrients, or both.
Some patients with SVT have increased troponin levels
without signs of coronary artery disease [14]. The exact
mechanism of myocardial injury and elevated troponin re-
lease in SVT is unclear. It may be due to an increase in
oxygen consumption by the myocardium during tachy-
cardia. Also, a reduction of the oxygen supply to the myo-
cardium due to the shortened diastole with subsequent
subendocardial ischemia during tachycardia is possible
[15]. Although cTnI elevation in patients presenting to the
hospital with SVT is well recognized, the prevalence,
predictors, and prognostic significance of cTnI elevation
associated with SVT presentation are not known. Mild
elevation of cTnI is common in patients presenting to the
hospital with SVT, and is associated with increased risk of
future cardiovascular events [16].
In most patients, either conservative management or
noninvasive stratification seems to be sufficient; an inva-
sive strategy could then be reserved only for high-risk
patients [15]. The presence of tachycardia sufficient to
warrant hospital admission can raise troponin, and this
should be viewed in context when a decision on angio-
graphy is to be taken [17]. In cases where methylpheni-
date is suspected to have caused coronary artery spasm,
the medical treatment should consist of coronary vasodi-
lators, such as nitrates and calcium channel-blockers
[10,11]. Furthermore, CMR thanks to high spatial reso-
lution and tissue characterization, can be crucial in iden-
tifying myocardial damage and its endocardial (ischemic
damage) or midwall/epicardial localization (non ische-
mic damage). Particularly, T2 weighted images permit
identification of myocardial damage. Delayed contrast
enhancement permits identification of the extent of scar
tissue. In the absence of a definite and clear diagnosis of
disease, we think that the identification of damage location
is necessary to confirm myocardial damage due to coron-
ary disease (acute MI with normal coronary arteries) or to
identify damage due to methylphenidate. The lack of a
CMR scan is a limitation in our case report. Our depart-
ment received the adverse effect report from the physician
three weeks after the patient was dismissed from the
hospital. Routinely, serum is only kept for 8 days after
dismissal, therefore, serum measurements of methylphe-
nidate or venlafaxine was not available.
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To our knowledge this is the first case report in which
the use of methylphenidate, in combination with venla-
faxine, both in therapeutic doses, is associated with high
levels of cardiac troponin, suspicious of acute coronary
syndrome. We speculate that methylphenidate could
give this effect based on its arrthymogenic potential in
higher doses, its potential to cause coronary artery vaso-
spasms, or both. Our case should be kept in mind before
a diagnosis of infarction is given or decision to perform
coronary angiography is made, in patients who use me-
thylphenidate or related substances. CMR could be of
diagnostic value in such cases.
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